News and Trends 8 Jan 2018 And We’re Off! First Patient Dosed in this Spanish Biotech’s Rare Disease Trial …that don’t have a donor. This leaves the door open for Minoryx to target adrenomyeloneuropathy with MIN-102, as well as other CNS indications going forward. The company has come a… January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 3 Apr 2018 Seven Expert Tips on How to Grow a Successful Biotech Startup …ago and has just started communicating to the world his goal of treating CNS disorders using RNA technology. “That becomes a whole paradigm shift,” says de Vlaam. “From having everyone… April 3, 2018 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 12 Jul 2023 Medicon Valley: how the initiative shaped biotech ecosystems in Denmark and Sweden …including diabetes, central nervous system (CNS) diseases and the microbiome. Medicon Village: connecting Sweden’s life science ecosystem While Medicon Valley Alliance pursues binational development in life sciences, Medicon Village, which… July 12, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Oct 2017 Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub …managed to get its Parkinson’s drug approved earlier this year. In doing this, it became one of the first biotechs in the EU with an approved CNS drug. Xadago tackles… October 10, 2017 - 7 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2024 Eight companies spearheading Philadelphia’s biotech industry …therapies for patients suffering from central nervous system (CNS) disorders. The company’s primary focus is on creating one-time gene therapies designed to address the underlying pathology of neurodegenerative diseases. Passage… May 21, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases …continue focusing on neurokinins, neuropeptides found in the CNS that stimulate nerve receptors. KanDy spun out from NeRRe to concentrate on a new, dual neurokinin antagonist. NeRRe focuses exclusively on… November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 29 Apr 2024 Can Brazil make cell and gene therapy costs affordable for all? …chief executive officer (CEO) of Vyro Bio, a Brazilian company developing next-generation viral immunotherapies to treat aggressive, fast-growing forms of central nervous system (CNS) tumors. “Nowadays, with the development of… April 29, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Jan 2024 The biggest private biotech investments in December 2023 The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players… January 10, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 May 2023 The biggest private biotech investments in April 2023 …B financing to support phase 1 and 2 trials of its human pluripotent stem cell candidates for lung diseases, degenerative joint diseases, central nervous system (CNS) diseases, and more. Other… May 5, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 New Gene Therapy for Parkinson’s will be Developed in the UK …a therapeutic gene in specific neuron subpopulations within the central nervous system (CNS). This approach of addressing only specific targets has the potential to cut down on side effects and… November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 2 Oct 2023 PIPEs in biotech fundraising: is this growing trend fueled by economic uncertainty here to stay? …the plug on its lead gene therapy candidate for the treatment of a rare central nervous system (CNS) disorder, following a U.S. Food and Drug Administration (FDA) meeting, it now… October 2, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 7 Jan 2026 Top biotech deals in December 2025 …the FDA nod to begin first-in-human studies to address diseases affecting the central nervous system (CNS) like multiple sclerosis later this year. As part of the collaboration, the Chinese biotech will gain a minority equity stake in Formation’s… January 7, 2026 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email